CLOs on the Move

Jaguar Health

www.jaguar.health

 
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jaguar.health
  • 201 Mission Street Suite 2375
    San Francisco, CA USA 94105
  • Phone: 415.371.8300

Executives

Name Title Contact Details
Jonathan Wolin
Chief Compliance Officer, Corporate Counsel Profile
Jonathan Wolin
Chief of Staff, Chief Compliance Officer and General Counsel Profile

Similar Companies

Athenex

Athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. The company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. Our business includes medical technology innovation centers and a unique manufacturing supply chain across both China and North America. Through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Accredo Nova Factor

Accredo Nova Factor is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Gastro Health

We are a medical group of physicians and health professionals that specialize in gastrointestinal disorders, nutrition and digestive health. Our offices are conveniently located throughout South Florida, Orlando and Fort Myers.

Kalypsys

Kalypsys is a clinical stage pharmaceutical company that is advancing the way drugs are discovered and developed. We seamlessly integrate our capabilities in drug discovery, medicinal chemistry and translational medicine with proprietary automated

Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, we are committed to changing the lives of people with these life-threatening conditions. Across the organization, our team is united by our passion for making a difference, and committed to pushing ideas as far and as fast as possible. The needs of people living with rare diseases are at the center of our inventive science, our commercial organization, and our clinical programs. Every member of the Amicus Therapeutics team works to make a meaningful difference for the communities that we serve. Several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. Our global footprint spans 27 countries, including our global headquarters in Cranbury, NJ and international headquarters in Gerrards Cross UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain.